Founded in 1997, Cytokinetics Inc. focuses on muscle biology, developing muscle activators and inhibitors that improve overall function. These medications most often serve patients with cardiovascular or neuromuscular disorders. After an IPO in 2004, the company has continued to grow with licensing and funding deals the world over.
Cytokinetics Inc. (NASDAQ: CYTK) Change
As Cytokinetics grows, it is riding positive news. The stock is up over $8 at press time, totaling more than a 45% change. Over the past year, the stock has risen, experienced a selloff, and grown from that selloff only to drop once again. The most recent positive news involving the company signifies yet another major jump in its value.
Why is CYTK Moving?
Cytokinetics, as reported by Benzinga News, is reporting positive results from the first two cohorts of its CK-274 medication for hypertrophic cardiomyopathy (HCM). With Phase 3 trials set to begin before the end of 2021, the firm should remain in the news and continually see increases in its stock price.
Where to Buy Cytokinetics Inc. Stock
Use this list of brokers curated by Benzinga. Choose the broker that you are most comfortable with, complete a trade today and buy into CYTK stock before its price jumps once again.
Stay Ahead of the Game on CYTK
Staying ahead of the game on CYTK stock is just as important as investing. You want to know how stocks are performing, review current events and make wise choices to increase your net worth.
Data for Cytokinetics Inc. as of July 19, 2021
Summary of Cytokinetics Inc. as of July 19, 2021:
Price Change: $19.230 to $27.914
52 Week Low: $14.71
52 Week High: $30.14
Market Cap: $1.386B
P/E Ratio: –
Dividend Yield: –
Significant Dates for Cytokinetics Inc.:
Next Earnings Date: August 5th, 2021
Last Earnings Date: May 6th, 2021, EPS of $-0.660
Ex-Dividend Date: –
Dividend Payment Date: –
Technical Data of Cytokinetics Inc. as of July 19, 2021:
RSI: 74.7 ? Bullish
MACD: Signal Line (-0.6378) Over MACD (0.6392) ? Bearish
Bollinger Bands: Price ($27.914) 20-Day SMA ($20.2628), Lower Band ($16.6871), Upper Band ($25.1229) ? Neutral
(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
